Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of [177Lu]Lu-DWJ155 Therapy and [68Ga]Ga-DWJ155 Imaging in Solid Tumors
jRCT2031260248Phase 1Recruiting
- Sponsor
- Novartis
- Start
- Jun 2026
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Beta-minus Emitters → Radiopharmaceuticals
01
Overview
Phase 1, open-label trial of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in breast cancer, non-small cell lung cancer (NSCLC), gastric cancer (GC) and 1 more (2 cohorts), sponsored by Novartis. Primary endpoints: Incidence and severity of adverse events and serious adverse events, Dose-limiting toxicities (DLTs) and 2 more. Started Jun 2026; status: recruiting.
02
Drugs
[177Lu]Lu-DWJ155[68Ga]Ga-DWJ155
03
Conditions
breast cancernon-small cell lung cancer (NSCLC)gastric cancer (GC)esophagogastric junction cancer
Beyond the preview
Go deeper on jRCT2031260248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260248.